Healthpeak Properties, Inc. (DOC) Balance Sheet

The jump in total assets alongside a rise in total debt from $9.4B to $9.7B over the same window suggests the balance sheet was reshaped by a transformational transaction rather than steady rate-base growth. Investors should monitor whether the incremental asset base is generating returns in line with the pre-merger portfolio, since the reported ROE of 0.2% in 2026Q3 provides little evidence of accretive deployment yet.

The inconsistency between the sub-$0.5B PPE readings in prior quarters and the $18.9B figure in the latest quarter points more toward a reporting or consolidation change than a true asset revaluation, and the data cannot confirm which view is correct. Given management's stated lab tenant credit concerns, the Life Science component may carry the greater occupancy and re-leasing risk, though the supplied data do not allow that exposure to be quantified.

The decline in leverage ratio reflects both rising book equity to $7.9B and a modest decrease in total debt from its peak, which may indicate deliberate deleveraging after the combination. However, the reported D/E figures appear inconsistent with typical healthcare REIT capital structures, so investors should verify the debt definition before relying on the trend for covenant or refinancing assessments.

The 2026Q2 cash peak coincided with the largest reported capital expenditure outflow, implying that cash on hand was likely raised or retained specifically to fund development and integration spending. With the latest cash position at $514.3M against a $9.7B debt stack, the buffer appears adequate for near-term obligations but thin relative to the scale of the Life Science development pipeline, warranting monitoring of revolver availability.